McKinley Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

McKinley Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-735,307	Closed	-$2.02M	–	360
2017 Q4	$2.02M	Buy	735,307 +406,688	+124%	+$1.25M	0.1%	155
2017 Q3	$1.11M	Buy	328,619 +5,011	+2%	+$13.9K	0.05%	229
2017 Q2	$799K	Hold	323,608	–	–	0.03%	247
2017 Q1	$735K	Buy	323,608 +141	+0%	+$312	0.03%	265
2016 Q4	$686K	Buy	+323,467	New	+$903K	0.03%	268
2014 Q3	–	Sell	-450,047	Closed	-$4.36M	–	401
2014 Q2	$4.36M	Sell	450,047 -19,467	-4%	-$174K	0.18%	133
2014 Q1	$3.9M	Sell	469,514 -21,086	-4%	-$181K	0.16%	134
2013 Q4	$4.14M	Buy	490,600 +37,437	+8%	+$315K	0.16%	130
2013 Q3	$3.61M	Buy	453,163 +285	+0.1%	+$2.29K	0.16%	136
2013 Q2	$3.5M	Buy	+452,878	New	+$3.53M	0.18%	124

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

McKinley Capital Management's PDLI Position: Q1 2018 in Review

McKinley Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2018, closing a stake of 735,307 shares — an estimated $2.02M sold.

McKinley Capital Management first reported a position in PDLI in Q2 2013 and held it in 10 quarters. The position peaked at $4.36M in Q2 2014. 176 funds tracked by Wall St. Rank hold PDLI as of Q1 2018.

McKinley Capital Management reported no remaining PDL BioPharma, Inc. position as of Q1 2018 after selling out during the quarter.
McKinley Capital Management sold 735,307 PDL BioPharma, Inc. shares in Q1 2018, an estimated $2.02M.
McKinley Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 10 quarters.
McKinley Capital Management's PDL BioPharma, Inc. position peaked at $4.36M in Q2 2014.
176 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2018.

Based on McKinley Capital Management's 13F filing for Q1 2018, filed 4 May 2018.